Navigation Links
PRI Condemns PEPFAR Amendments
Date:2/6/2008

FRONT ROYAL, Va., Feb. 6 /PRNewswire-USNewswire/ --- Population Research Institute has joined other pro-life groups in condemning amendments to the President's Emergency Plan for AIDS Relief (PEPFAR).

PEPFAR is up for reauthorization on Thursday, February 14, 2008, in the House Foreign Affairs Committee. According to PRI's president Steven Mosher, the preliminary drafts have been compromised by amendments that put the money directly in the hands of known population controllers.

"It would be better if President Bush had never proposed PEPFAR, than to have 50 billion dollars hijacked by abortion-promoting, chastity-mocking, anti-people groups like IPPF, UNFPA, and the Chinese government," said Mosher. "If the amendments promoted by the Democrat majority are passed, a veto will be the President's only option."

These amendments include "family planning" language that does not exclude abortion, lifting important abortion restrictions imposed by the Mexico City Policy, a removal of the anti-prostitution pledge, and a full integration of family planning services with HIV aid services.

PRI urges pro-lifers everywhere to contact the members of the House Foreign Affairs Committee and encourage them to vote against this bill. Information about this committee can be found at http://www.foreignaffairs.house.gov.

The Population Research Institute (PRI) was founded in 1989 by Fr. Paul Marx, OSB, PhD and is dedicated to: (1) ending human rights abuses committed in the name of "family planning," (2) opposing outdated social and economic paradigms premised on the myth of overpopulation, (3) informing the public about the social and economic benefits of moderate population growth, and (4) promoting pro-natal and pro-family attitudes and policies worldwide.


'/>"/>
SOURCE Population Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Catholic Health Association Condemns Denial of Health Insurance for Children
2. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
3. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...Texas observed that Viagra could be used to treat ...but based on a small experiment in healthy young m...ly to people with chronic heart and lung disease. ...ul in treating people with pulmonary hypertension ...
... soon be available for patients needing root canal...end to the dreaded drill. Scientists say laser tre...thout damaging the healthy nerve. They added that...damage to the rest of the teeth. Researchers said ...
...sible connection to autism. A study in this week's...ith autism are no more likely than those without i.... // Study investigators from Boston University id...ompared them to children without autism. They revi...
...s that pre and post exercise stretching does littl...gym routines or exercise classes// you'll be well ...he session to prepare your muscles. It's always as...the following day and reduce the risk of injury li...
Other Medicine News:
(Date:7/23/2008)...- Sound Pharmaceuticals (SPI) has filed,an Investi... clinical,testing of a proprietary formulation of ... hearing loss or ototoxicity. The oral capsule,con...ced stage lung cancer,and head and neck cancer pat...marks the second development program for SPI to en...
(Date:7/23/2008)... FluoroPharma Inc., a company developing,breakthro...sion Tomography,(PET) market, announced positive P...beled tracer for myocardial perfusion imaging. BFP... to complete Phase I clinical,development., BFPET...ood flow in the,heart (myocardial perfusion). Myoc...
(Date:7/23/2008)...ire/ -- InCode BioPharmaceutics, Inc.,an emerging...nical test,results demonstrating the utility of th... the rare chronic blood disorder paroxysmal noctur...l be presented at the XXII,International Complemen...08., The only treatment currently available for P...
(Date:7/23/2008)... Work with Protein Therapeutics that Mod...AMBRIDGE, Mass., July 23 /- Taligen T...a corporate growth plan with the,appointment of Ab...d the,establishment of its headquarters in Cambrid...D., a co-founder of the company who remains presid...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 1Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 2Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 4AAHC Examines Nations Clinical Trials Infrastructure 620 1AAHC Examines Nations Clinical Trials Infrastructure 620 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 1Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 3Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 1Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 2Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 3Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 4Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 5Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 6Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 7Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 8Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 9Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 10Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 11Aflac Incorporated Announces Third Quarter Results Declares Fourth Quarter Cash Dividend 4411 12
...THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007...ced final results of a U.S.,Phase 2 study of Proel...ymptoms of uterine fibroids. This study suggests t...ally highly,significant improvement in symptoms as...ll tolerated., Study Details and Results , This 12...
...PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - A...nced the publication by its,majority-owned subsidi...strating the anti-proliferative effect of the siRN...f its lead anti-cancer,compound, CALAA-01., The pa...eotide,Reductase Subunit RRM2 Reduce Cell Prolifer...
Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: